SCHEMBL3387689

SCHEMBL3387689

CC(C)(C)[SiH2]OC(C)(C)c1ccc(N)cn1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 4/20 0.37
POLB P06746 1/20 0.37
RAB9A P51151 1/20 0.37
KEAP1 Q14145 1/20 0.33
CA12 O43570 1/20 0.31
CA1 P00915 1/20 0.31
CA2 P00918 1/20 0.31
CA4 P22748 1/20 0.31
CA6 P23280 1/20 0.31
CA5A P35218 1/20 0.31
CA7 P43166 1/20 0.31
CA9 Q16790 1/20 0.31
CA13 Q8N1Q1 1/20 0.31
CA14 Q9ULX7 1/20 0.31
MEN1 O00255 2/20 0.30
KMT2A Q03164 2/20 0.30
ALDH1A1 P00352 1/20 0.30
BRCA1 P38398 1/20 0.30
HBB P68871 1/20 0.30
HSD17B10 Q99714 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL508438 0.79 GBA1 (0.33) KDM4EALDH1A1
SCHEMBL17653958 0.78 HSD17B10 (0.43) KDM4EPOLBRAB9AKEAP1CA12
SCHEMBL14914729 0.73 KDM4E (0.46) KDM4EPOLBMEN1KMT2AALDH1A1
SCHEMBL30004124 0.73 KDM4E (0.46) KDM4EPOLBRAB9AKEAP1CA12
SCHEMBL2367892 0.73 KDM4E (0.46) KDM4EPOLBRAB9AKEAP1CA12
SCHEMBL9521933 0.72 MAPK1 (0.50) KDM4EPOLBRAB9ACA12CA1
SCHEMBL4406050 0.72 ALDH1A1 (0.44) KDM4EPOLBRAB9AMEN1KMT2A
SCHEMBL21675704 0.70 KDM4E (0.40) KDM4EPOLBRAB9AKEAP1CA12
SCHEMBL13653889 0.70 KDM4E (0.40) KDM4EPOLBRAB9AKEAP1CA12
SCHEMBL643188 0.69 KDM4E (0.39) KDM4EPOLBRAB9AHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100056524-A1 Compound MEDICAL RESEARCH COUNCIL TECHNOLOGY (GB) 2010-03-04 US disclosed
WO-2009122180-A1 PYRIMIDINE DERIVATIVES CAPABLE OF INHIBITING ONE OR MORE KINASES MEDICAL RESEARCH COUNCIL (GB) 2009-10-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100056524-A1 Compound NR3C2, NR3C1, NR2E3 KDM4E 2587/4885POLB 4178/4885RAB9A 3551/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.